Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2021-12-10 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
募集资金置换专项审核报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by an accounting firm (希格玛会计师事务所) regarding the use of raised funds to replace self-raised funds previously invested in projects by the company 天康生物股份有限公司. It references specific regulatory guidelines related to the management and use of raised funds, and includes an auditor's opinion on the accuracy and compliance of the company's management explanation. The document is titled as a "募集资金置换专项审核报告" (Special Audit Report on the Replacement of Raised Funds) and contains detailed audit procedures and conclusions. It is not a full annual or interim report, nor a general audit report on financial statements, but a standalone audit report focused on a specific regulatory compliance matter. The document length is about 3207 characters, which is consistent with a standalone audit report rather than a full annual report or earnings release. Therefore, the most appropriate classification is Audit Report / Information (AR). Q4 2021
2021-12-10 Chinese
关于使用募集资金置换预先投入募投项目自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tian Kang Biological Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects. It details the approval by the board and supervisory committee, references regulatory approvals, and includes opinions from independent directors, auditors, and sponsors. The document is about the company's capital management and use of funds, specifically the replacement of self-raised funds with raised funds. It does not contain financial statements or quarterly/annual financial results, nor is it a report or transcript. The document is a formal announcement related to capital/financing activities, specifically the use of raised funds and capital structure changes. The document length is under 5,000 characters and is a detailed announcement, not a report publication notice. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-12-10 Chinese
第七届董事会第二十二次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 22nd interim meeting of the 7th Board of Directors of Tian Kang Bio Co., Ltd. It details voting results on proposals related to the use of raised funds and includes references to related announcements and independent directors' opinions published elsewhere. The document does not contain financial statements or detailed financial data but rather reports on board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management. The document length is short and it is not a full report or financial statement, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement since it contains substantive board meeting resolution content rather than just a notice of report publication.
2021-12-10 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of idle raised funds by Tian Kang Bio Co., Ltd. It references regulatory approvals, specific fundraising amounts, usage plans, and compliance with relevant securities laws and stock exchange rules. The document includes detailed financial figures related to the raised funds and their usage, as well as opinions from the board, independent directors, and supervisory board. It is not a full annual or interim report, nor is it a brief announcement or a certification letter. It is a specialized audit or verification report focused on the use of raised funds, which fits the category of an Audit Report / Information (AR). The document length is 3177 characters, which is relatively short but contains substantive financial and compliance information, not merely an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2021
2021-12-10 Chinese
第七届监事会第十五次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 15th (extraordinary) meeting of the 7th Supervisory Board of Tian Kang Bio Co., Ltd. It details voting results on proposals related to the use of raised funds and temporary supplementation of working capital. The document includes voting counts and references to related announcements but does not contain financial statements or detailed financial data. It is a corporate governance announcement about board decisions rather than a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on meeting resolutions, not a full report or regulatory filing.
2021-12-10 Chinese
独立董事独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' special opinion on the company's use of raised funds, referencing regulatory guidelines and approvals related to the use of proceeds from fundraising. It discusses compliance with securities regulations and internal company rules regarding the replacement of self-raised funds with raised funds and the temporary use of idle raised funds to supplement working capital. The document is a formal opinion letter from independent directors, not a full financial report or audit report. It is a regulatory compliance-related statement, not an annual report, audit report, or earnings release. Given the nature and length (948 characters), it is not a full report but a regulatory filing related to governance and compliance. Therefore, the best classification is Regulatory Filings (RNS).
2021-12-10 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.